Background. Hyperactivation of phosphoinositide 3-kinase (PI3K) signaling is common in cancers, but the precise role of the pathway in glioma biology remains to be determined. Some understanding of PI3K signaling mechanisms in brain cancer comes from studies on neural stem/progenitor cells (NSPCs), where signals transmitted via the PI3K pathway cooperate with other intracellular pathways and downstream transcription factors to regulate critical cell functions. Methods. To investigate the role of the PI3K pathway in glioma initiation and development, we generated a mouse model targeting the inducible expression of a PIK3CA H1047A oncogenic mutant and deletion of the PI3K negative regulator, phosphatase and tensin homolog (PTEN), to NSPCs. Results. Expression of a Pik3ca H1047A was sufficient to generate tumors with oligodendroglial features, but simultaneous loss of PTEN was required for the development of invasive, high-grade glioma. Pik3ca H1047A -PTEN mutant NSPCs exhibited enhanced neurosphere formation which correlated with increased Wnt signaling, while loss of cAMP response element binding protein (CREB) in Pik3ca H1047A -Pten mutant tumors led to longer symptom-free survival in mice. Conclusion. Taken together, our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis and that disruption of downstream CREB signaling attenuates tumor expansion. 
Genetically engineered mouse models have demonstrated that various genes can initiate glioma development, with the first models expressing constitutively activated mutant growth factor receptors, including epidermal growth factor receptor (EGFR), or mutated signaling molecules, including Ras and Akt. 1, 2 Genes enabling the initiation of high-grade gliomas (HGGs) include combinations of NF1, TP53, PTEN, Akt, Ras, and INK4a/ARF. [3] [4] [5] [6] Models targeting glial cells, 1, 4, 7 oligodendrocyte precursor cells, astrocytes, or neurons also initiate HGG. 8, 9 The role of brain tumor stem cells (BTSCs) has been demonstrated by targeting genetic mutations/deletions in neural stem/progenitor cells (NSPCs), 2, 3, 5, 6, [9] [10] [11] highlighted by a study demonstrating that ablation of BTSCs inhibits tumor growth. 12 The signaling pathways driving HGG overlap with those activated in other cancers and involve complex interactions between oncogenes and tumor suppressors, many of which regulate the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. These pathways trigger a cascade of downstream kinases leading to the activation of transcription factors, including the cAMP response element binding protein (CREB), which is upregulated in glioblastoma (GBM) and has a role in NSPC and GBM cell proliferation. 13, 14 Emerging evidence suggests that oncogenic PI3K and MAPK signals converge with Wnt signaling to regulate cancer cell growth and proliferation 15 and that in GBM, Wnt signaling has a role in cancer stem cell maintenance. 16 When one considers the upstream components of the PI3K pathway, including EGFR, the PI3K catalytic and regulatory subunits, as well as the pathway's major negative regulator, phosphatase and tensin homolog (PTEN), 63% of HGGs exhibit an alteration in at least one of these genes. 17 A major catalytic subunit of PI3K, encoded by the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), is among the 3 top oncogenic drivers in GBM; the other drivers are EGFR and TP53. 18 Indeed, PIK3CA mutations are reported in up to 17% of low-and high-grade pediatric and adult brain cancers, with higher-grade and treatment-resistant tumors exhibiting higher mutation rates. 17, 19 Full activation of the PI3K pathway not only requires enhanced catalytic activity to drive key downstream kinases such as Akt but also requires the inactivation of the phosphatase activity of PTEN. 20, 21 Deletion of PTEN in NSPCs leads to enhanced proliferative activity in the stem cell niche but no tumor development. 22, 23 Pten deletion in combination with p53 and/or Rb1 loss results in the development of astrocytic high-grade tumors. 4 However, the effects of pro-oncogenic mutations involving the PI3K catalytic (p110α) and regulatory (p85) subunits have not been investigated.
To better understand the role of the PI3K pathway, we targeted the PI3K pathway in mouse NSPCs by conditional activation of an oncogenic mutation in Pik3ca, the gene encoding the PI3K p110α catalytic subunit, 24 in combination with PTEN deletion and show that these mutations are sufficient to initiate tumor growth. To investigate the downstream transcriptional programs regulated by the PI3K pathway, we deleted CREB and show that CREB loss slows tumor growth and leads to a less aggressive phenotype.
Materials and Methods

Ethics Statement
Mouse experiments were carried out with the approval of The University of Melbourne, School of Biomedical Sciences (AEC No 1112336.1) and Peter MacCallum Cancer Center (AEEC No. E406) Animal Ethics Committees.
Mouse Breeding
Mice heterozygous for a latent Cre recombinase (Cre)-inducible knock-in of the Pik3ca H1047R mutation (Pik3ca H1047R-lox ) 24 and/or 2 Cre-inducible Pten deletion alleles (Pten loxP/loxP ) 23 were crossed with mice expressing a single (heterozygous) Nestin-CreER T2 transgene. 25 Further F1 crosses generated mice which were heterozygous for mutant Pik3ca H1047R (Pik3ca H1047R-lox -Nestin-CreER T2 ) and homozygous Pten deletion (Pten loxP/loxP -Nestin-CreER T2 ) (Pten ∆ ). Mice were housed and genotyped as previously described. 24, 26 See Supplementary Methods for details.
In Vivo Tumor Induction
Control
(Pik3ca H1047R-lox -Pten lox/lox ), double mutant (Pik3ca H1047R-lox -Pten lox/lox -Nestin-CreER T2 ), or triple mutant (Pik3ca H1047R-lox -Pten lox/lox -Creb lox/lox -Nestin-CreER T2 ) mice were treated with tamoxifen at either 1 day or 6-8 weeks of age, as described previously. 27 
Histology and protein analysis
Brain tissue was fixed by intracardiac perfusion with 4% paraformaldehyde, and immunohistochemistry was performed as described previously. 26 For western blotting, cells were lysed in radioimmunoprecipitation assay buffer. Antibodies are detailed in the Supplementary Methods.
Importance of the study
This study demonstrates that PI3K mutations in NSPCs can initiate glioma-like tumors. Mutant NSPCs exhibited increased PI3K signaling but also showed enhanced CREB transcription factor activation, which promotes cell proliferation, as well as enhanced Wnt signaling, which promotes self-renewal. Tumors were switched to a less malignant state by simultaneous deletion of CREB, raising the possibility that CREB may be an important anticancer drug target.
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NSPC Culture
Refer to the Supplementary Methods for isolation of NSPC protocol. For experiments involving NSPCs, mutant NSPCs were generated by transient (24 h) treatment with 0.02 mg/ mL 4-hydroxy-tamoxifen (4-OHT) in ethanol to induce Cremediated recombination of floxed alleles, while control cells were derived from the same genotype but treated with vehicle only (ethanol). 4-OHT was removed after 24 h and never included in the medium in further experiments.
Cell Cycle Analysis
Cells in phosphate buffered saline (PBS) were fixed in cold 100% ethanol. Cells were washed 3 times with PBS and incubated with 4′,6′-diamidino-2-phenylindole (DAPI) (5 μg/mL; Thermo Fisher Scientific) for 15 min on ice. Cells were then washed, suspended in PBS, and analyzed by fluorescence activated cell sorting (LSR Fortessa 405 nm). Cells were gated with forward scatter width versus DAPI (405 nm) to exclude doublets and debris. A histogram of DAPI versus count was generated and analyzed using FlowLogic v6 software to identify the population (%) of cells in each of the cell cycle phases.
Proliferation Assays
Resazurin solution (Sigma) was diluted in media and added to wells, in 96-well plates, to obtain a 10% v/v solution before incubation for 3 h at 37°C. Plates were analyzed using the EnSpire Plate Reader (PerkinElmer).
Migration Assay
Single neurospheres in Dulbecco's modified Eagle's medium F12 with growth factors and supplements (see NSPC Culture method, above) were placed into a 96-well plate (1 sphere/well) for 48 h and assayed using the Trevigen 96-well 3D spheroid basement membrane extracts cell invasion assay kit (Bio Scientific). Neurospheres were incubated either with (test) or without (control) addition of invasion matrix for 48 h. Spheres were photographed and invasion area was calculated by measuring the area of spread and subtracting the control neurosphere invasion area using ImageJ (http://rsb.info.nih.gov/ij/index.html).
Extreme Limiting Dilution Analysis
Neurospheres were dissociated and plated in suspension media at 20, 10, 5, and 1 cell per well with 24 replicates per cell density. Wells were photographed after 7 days and the number of wells with one or more spheres greater than ~20 µm diameter was scored. Data were analyzed using online analysis 28 (http://bioinf.wehi.edu.au/software/elda/).
Statistical analysis
Student's t-test was used and results presented as mean ± SD or SEM, as indicated in relevant sections. P < 0.05 (*) was considered significant.
Results
Activation of Pik3ca H1047R Expression in NSPCs Is Sufficient for Tumor Initiation but Simultaneous Deletion of Pten Is Necessary for the Development of Invasive Tumors
The data from all mice analyzed are summarized in Table 1 . Control Pik3ca H1047R-lox -Pten loxP/loxP mice without the Nestin-CreER T2 transgene but treated with tamoxifen did not develop neurological symptoms or show evidence of tumor growth over the experimental time window of >200 days (Fig. 1) . Single mutant Pten ∆ mice showed no overt abnormalities but did exhibit increased subventricular zone (SVZ) cellularity and proliferation compared with 
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controls (Fig. 1A) , as reported previously. 23 Examination of single mutant Pik3ca H1047R mouse brains between 42 and 222 days post tamoxifen administration revealed the presence of tumors in/adjacent to the lateral ventricles (LVs) (Fig. 1A) . Tumors from 4 Pik3ca H1047R mice exhibited numerous cells with perinuclear halos or "fried egg" cells with oligodendrocyte transcription factor (Olig2) expression; features associated with oligodendroglioma ( Fig. 1A and Supplementary Figure S1 ).
Tamoxifen treatment of Pik3ca H1047R-lox -Pten loxP/loxPNestin-CreER T2 (referred to as Pik3ca H1047R -Pten ∆ ) 6-to 8-week-old mice resulted in a completely penetrant (100%; 30/30 mice) neurological phenotype 55-90 days after tamoxifen administration. An early sign of ill health was a decline in body weight (Fig. 1B) , followed by the appearance of progressively more severe neurological symptoms. The first neurological manifestation was ataxia, followed by sporadic seizures and a gradual increase in seizure frequency and length. The experimental endpoint was when weight loss was more than 15% of the start weight and/ or when seizures occurred more than 3 times per day, and when a seizure lasted more than 1 min. Double mutant mice reached the experimental endpoint between 55 and 90 days (Fig. 1C) . Single mutant Pik3ca H1047R expression or Pten mice showed no symptoms or reduced survival over 200 days (Fig. 1B, C and Table 1 ). When Pik3ca H1047R -Pten ∆ mutations were activated in 1-day-old newborn mice (P1) via tamoxifen treatment of the mother and transmission of the tamoxifen to pups via the mother's milk, the pups began exhibiting severe neurological symptoms between 28 and 43 days (Fig. 1C) ; faster than in adult mice treated with tamoxifen but with morphologically similar tumors to adult mice.
Adult Pik3ca H1047R -Pten Δ brains exhibited hypercellularity of the SVZ, with multiple tumor nodules protruding into the LV (Fig. 1D, upper panel) and tumors filling the anterior LV (Fig. 1D lower panels) . Hypercellular clusters were present along the SVZ with tumor cell migration into tumor nodules ( Fig. 2A, B) . Tumor cells invaded the brain parenchyma and white matter tracts, including the corpus callosum (Fig. 2C) . Apoptotic cells and mitoses were present, lying among atypical, irregularly arranged tumor cells and blood vessels (Fig. 2D and Supplementary Figure S2A) . Rosette-like cell arrangements were noted in one tumor (Supplementary Figure S2B) .
Pik3ca H1047R -Pten Δ tumors expressed glial fibrillary acidic protein (GFAP) (Fig. 2E ) and β-III-tubulin (Tuj1) (Fig. 2F) : evidence of glial and neuronal differentiation. Phosphorylated (p)Akt and pRps6 were expressed in tumor cells (Fig. 2G) , demonstrating PI3K pathway activation. Activation of phospho-extracellular signal-regulated kinase (ERK)1/2 (pERK1/2 [pMAPK]) and phospho-CREB (pCREB) expression showed that other oncogenic signaling and transcriptional pathways were coactivated (Fig. 2G) . Ki67 and nestin expression demonstrated that tumors also harbored proliferating, immature cells, with some Olig2-positive cells observed (Supplementary Figure S3) . Overall, Pik3ca H1047R -Pten Δ tumors exhibited heterogeneous features, consistent with high-grade (grade III) astrocytic tumors.
Mutant NSPCs Exhibit Enhanced PI3K Signaling and Subtle Shift in Cell Cycle
To investigate the cellular characteristics of mutant cells, NSPCs were isolated from the SVZ of 4-weekold mice carrying the Nestin-Cre transgene and latent Pik3ca H1047R , Pten lox/lox , and double mutant Pik3ca H1047R -Pten lox/lox alleles. NSPCs were propagated as neurospheres, and mutations were activated using 4-OHT.
Comparison of PI3K pathway activation by expression analysis of pAkt(Ser473) in wild type (WT), Pik3ca H1047R -Pten Δ , Pik3ca H1047R , and Pten Δ NSPCs showed that PI3K activation was strongest in double mutant Pik3ca H1047R -Pten Δ NSPCs (Supplementary Figure S4) . Short-term proliferation assays revealed no significant differences between genotypes. Cell cycle phase analysis revealed subtle differences in S-phase, where Pik3ca H1047R -Pten Δ and Pten Δ NSPCs showed more cells in S-phase (DNAreplication phase) than both Pik3ca H1047R and WT control cells (Supplementary Figure S5) .
Incomplete Recombination Directed by the Nestin-Cre ERT2 Transgene PCR analysis of the Pten allele in NSPCs carrying the loxP alleles and the Nestin-Cre ERT2 transgene to determine DNA recombination efficiency following 4-OHT treatment showed that NSPC cultures harbored a mixture of mutant and nonmutant cells (Supplementary Figure S6) , irrespective of the presence or absence of further floxed alleles. Given reports showing that Nestin promoters may drive inefficient Cre-mediated recombination of some floxed alleles in NSPCs, 29 we surmised that the Nestin-Cre ERT2 transgene led to incomplete recombination of the Pten lox/lox allele in 4-OHT treated cells. In vivo, mosaic expression of the oncogenic mutations is sufficient for tumor initiation, 
NeuroOncology
since even a small population of mutant founder/initiating tumor cells can proliferate to give rise to the larger tumor mass and disease. Considering this, further in vitro experiments were performed using NSPCs derived from the SVZ of Pik3ca H1047R -Pten lox/lox -UBC-Cre ERT2 mice generated previously, 30 where Cre ERT2 expression under the control of the Ubiquitin promoter results in complete recombination in all cells exposed to 4-OHT, demonstrated by PCR (Supplementary Figure S6) and loss of PTEN protein (Supplementary Figure S7) .
Pik3ca H1047R -Pten Δ Mutant NSPCs Exhibit Abnormal Morphology and Enhanced Migration
Pik3ca H1047R -Pten Δ neurospheres formed loosely aggregated rough-edged spheres (Fig. 3A) compared with parental WT neurospheres. Moreover, mutant NSPCs had more filopodia compared with controls (Fig. 3A, B) , a feature associated with a more invasive, malignant phenotype in GBM. 31 Incorporation of the thymidine analog, 5-ethynyl-2ʹ-deoxyuridine (EdU) and flow cytometry analysis showed that Pik3ca H1047R -Pten Δ cells had a higher proliferation rate compared with WT cells (Fig. 3C) . Mutant cells showed enhanced pAkt expression and increased expression of cyclins B1 and D1 (Fig. 3D) .
Seeding single neurospheres into a gel matrix showed that Pik3ca H1047R -Pten Δ NSPCs migrated to cover more than 3 times the area compared with WT NSPCs (Fig. 3E, F) , demonstrating increased migratory capacity. Moreover, seeding cells at high density for 72 h showed that mutant NSPCs detached and migrated away from spheres, unlike control NSPCs at the same density (Supplementary Figure S8) .
Enhanced Sphere-Forming Capacity, Persistent Nestin Expression, and Wnt Pathway Activation in Pik3ca H1047R -Pten Δ Mutant NSPCs
To determine the long-term proliferation differences between mutant and control NSPCs, cumulative growth was measured over 8 passages (8 wk). Pik3ca H1047R -Pten Δ cells showed significantly higher cell numbers from week 2 onward and almost 4 times more cells by 8 weeks (Fig. 4A) . To investigate this difference, we examined the neurosphere-forming efficiency of NSPCs using extreme limiting dilution analysis (ELDA). 28 Pik3ca H1047R -Pten Δ cells (1 neurosphere forming unit [NSFU])/1.55 cells seeded) formed spheres more efficiently than control cells (1 NSFU/2.01 cells seeded) (Fig. 4B) . To test the neurosphere-forming stability of the NSPCs, we subjected the cells to alternating rounds of growth in neurosphere medium, serum-containing medium (to differentiate the cells), and a return to neurosphere medium (Fig. 4C) . Flow cytometry analysis demonstrated that the immature marker, nestin, was still expressed in 70% of Pik3ca H1047R , Pten Δ differentiated cells, compared with 52% of WT after 7 days (Fig. 4D) . Returning differentiated cells to serum-free neurosphere conditions revealed a significantly higher sphere-forming capacity in mutant cells (1 NSFU/15.4 cells seeded) compared with control cells (1 NSFU/36.0 cells seeded) (Fig. 4E) . Independent assessment of immature and differentiation markers using nestin+, GFAP+, and Tuj1+ cells grown on laminin for 5 days showed enhanced nestin+ cell stability in mutant NSPCs, under differentiating conditions ( Supplementary Fig. S9 ).
Phosphoprotein measurement showed an upregulation of phosphorylation of various PI3K/Akt pathway-associated factors in mutant NSPCs compared with WT cells (Fig. 5A) . To investigate the biological basis of the enhanced neurosphere-forming capacity in Pik3ca H1047R -Pten Δ NSPCs, we postulated that Wnt signaling was upregulated in mutant cells, due to the increase in glycogen synthase kinase 3 (GSK3)β phosphorylation and Wnt signaling. Analysis of NSPCs showed that β-catenin was expressed at higher levels in mutant nuclei compared with WT cells (Fig. 5B) , indicating activation of Wnt signaling. Messenger RNA expression of Wnt pathway stem-cell factors and targets was higher in mutant NSPCs compared with controls (Fig. 5C ). CHIR99021 ("CHIR"), a GSK3 inhibitor and Wnt pathway activator, increased neurosphere-forming potential of mutant NSPCs, which was 1:1 (spheres formed per cells seeded) for CHIR-treated NSPCs compared with 1:2.6 for vehicle-treated cells (Fig. 5D ). Upstream inhibition of the Wnt pathway using IWP-2 (inhibitor of Wnt processing) did not affect sphere-forming capacity compared with vehicle-treated mutant NSPCs.
Creb1 Deletion Ameliorates Malignancy of Pik3ca H1047R -Pten Δ Tumors
Pik3ca H1047R -Pten Δ tumors expressed high levels of pCREB (Fig. 2G) , and this expression overlapped with nestin and GFAP expressing SVZ cells (Fig. 6A) . We previously showed that mouse SVZ cells and human glioma express high levels of activated CREB (pCREB). 14, 32 To determine the contribution of CREB in brain tumor growth, we used Creb lox/lox mice 26 to generate triple mutant Pik3ca H1047R-loxPten lox/lox -Creb lox/lox -Nestin-CreER T2 mice, resulting in deletion of CREB, in addition to the Pik3ca and Pten mutations to generate Pik3ca H1047R -Pten Δ -Creb Δ mice.
CREB-deleted brain tumors exhibited the presence of large cells (Fig. 6B and Supplementary Figure S10 ) with little or no invasion into nontumor brain parenchyma (Supplementary Figure S10A) . CREB-deleted tumors showed a reduction in cell density compared with double mutant tumors ( Figure 6B , C and Supplementary Figure S10) , with 65% of the cell density of Pik3ca H1047R -Pten Δ tumors. Moreover, CREB mutant mice were symptom free for longer (median 125 days) compared with double mutant Pik3ca H1047R -Pten Δ mice (median 70 days) (Fig. 6D) .
NSPCs were isolated from Pik3ca H1047R-lox -Pten lox/loxCreb lox/lox -Nestin-CreER T2 mice and treated with 4-OHT, which led to efficient recombination of the Creb lox/lox allele (Supplementary Figure S6) , unlike the Pten lox/lox allele. Assays showed that proliferation was reduced in CREBdeleted NSPCs compared with Pik3ca H1047R -Pten Δ cells (Supplementary Figure S11B) . Cell cycle analysis showed that CREB mutant NSPCs had fewer (5.9%) S-phase cells and more (80.2%) G0/G1 phase cells compared with 
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Pik3ca H1047R -Pten Δ (12.8% S phase; 70% G0/G1 phase) NSPCs (Supplementary Figure S11C) . Sphere-forming capacity of Creb Δ NSPCs did not differ compared with Pik3ca H1047R -Pten Δ NSPCs (not shown).
Discussion
To our knowledge, no studies have demonstrated a direct involvement of PI3K subunit mutations in glioma in vivo. Large-scale sequencing data suggest that PIK3CA is a key driver of malignant astrocytic brain cancer. 18 Our study demonstrates that expression of constitutive active Pik3ca H1047R can initiate slow-growing oligodendroglial-like tumors when targeted to NSPCs. In patients, PIK3CA H1047R mutations are seen in both low-and high-grade gliomas, including anaplastic oligodendroglioma and glioblastoma. 17, 19 Homozygous loss of Pten led to increased SVZ cellularity but not tumor development, similar to the phenotype previously reported using Pten lox/lox -Nestin-Cre mice. 23, 33 Coexistent mutation of both PIK3CA and deletion of PTEN is rare in glioma patients but the combined genetic aberrations are not absolutely redundant. 34 Inactivation of PTEN and constitutive activation of PIK3CA, which led to maximal PI3K pathway activation (Fig. 3D) , 35 is presumably required to drive tumorigenesis, highlighting the importance of cooperative cancer-driving mutations which lead to robust PI3K pathway activation. Further, the Pik3ca mutation only affects p110α, while PTEN will affect both the p110α and other p110 subunits, including p110β, which has a role in glioma cell function, 36, 37 further enhancing PI3K signaling.
Pik3ca H1047R -Pten Δ NSPCs exhibited enhanced migratory properties and sphere-forming stem cell-associated characteristics, consistent with previous studies demonstrating that PI3K pathway activation promotes GBM cell migration, 38 neurosphere formation, and tumorigenicity of glioma stem cells. 39 Pik3ca H1047R -Pten Δ NSPCs maintained nestin expression and sphere-forming capacity even after Extreme limiting dilution analysis of NSPCs showing that Wnt pathway activation by pharmacological inhibition of GSK3β using CHIR99021 (2 µM) increases neurosphere-forming capacity of mutant NSPCs, while Wnt inhibition using IWP-2 (5 µM) reduces neurosphere forming capacity to WT control levels. All error bars are SEM from n = 3. *P < 0.05 or as indicated in Fig. 5D .
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forced differentiation, suggesting that Pik3ca H1047R -Pten Δ mutations stabilize stem cell properties, and, in a clinical setting, these mutations may impart stable, therapyresistant characteristics with enhanced capacity for tumor recurrence.
Phospho-GSK3β expression was increased in mutant NSPCs, suggesting hyperactivation of the Wnt pathway. 40 Wnt and PI3K signaling are commonly coactivated in stem cells, consistent with enhanced neurosphere-forming capacity of Pik3ca H1047R -Pten Δ mutant NSPCs. Wnt signaling is critical for maintaining efficient self-renewal of NSPCs 41, 42 and glioma stem cell self-renewal. 43, 44 The clinical importance of Wnt signaling in gliomas is highlighted by the correlation of Wnt factors with independent markers of poor prognosis. 45 We and others have shown that the kinase-inducible transcription factor CREB and its activated form, pCREB, are expressed in GBM 14, 46 and that CREB has a role in glioma cell proliferation. 14 Aside from the expected upregulation of the PI3K pathway factors in Pik3ca H1047R -Pten Δ tumors, the MAPK pathway was also upregulated, consistent with observations that CREB sits at a transcriptional convergence point of the PI3K and MAPK pathways. 14 CREB deletion in Pik3ca H1047R -Pten Δ NSPCs showed that mutant Pik3ca H1047R -Pten Δ -Creb Δ mice were symptom free for a longer time compared with double mutant Pik3ca H1047R -Pten Δ mice. CREB loss resulted in reduced tumor cellularity and larger tumor cells, suggestive of a less malignant, giant-cell GBM, which has a better prognosis compared with classical GBM. 47 Moreover, no invasion into white matter tracts was observed in triple mutant brains. This is the first in vivo data demonstrating that CREB deletion in tumor cells suppresses tumor growth, consistent with studies correlating aberrant CREB expression and activation with poor prognosis in many neoplasms, including lung 48 and breast. 49 Overall, our data lead us to propose a model in which the PI3K pathway is critical and sufficient for reprogramming normal NSPCs into tumor-initiating cells. Additionally, we show that mutation of the catalytic PI3K subunit, p110α, leads to transformation of NSPCs into low-grade oligodendroglial-like tumors but that simultaneous PTEN loss enhances oncogenesis, resulting in fast, aggressive tumor growth. As the PI3K mutant tumor cells mature, a CREB-dependent transcriptome is activated, which supports tumor growth. MAPK signaling is also coactivated, further enhancing CREB activation. The Wnt pathway is also hyperactivated and contributes to promoting NSPC self-renewal. Deleting CREB in tumor cells alters the tumor cell phenotype, slows tumor cell growth, and extends symptom-free survival. Recently developed experimental compounds which target CREB can inhibit tumor cell proliferation in vitro and in vivo. 50 Co-targeting archetypal oncogenic pathways, including PI3K, MAPK, and Wnt, as well as transcription factors such as CREB, may prove to be an effective therapeutic approach for difficult to treat cancers, including HGGs.
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